Evgenia Verrou

1.8k total citations
32 papers, 1.1k citations indexed

About

Evgenia Verrou is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Evgenia Verrou has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 15 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Evgenia Verrou's work include Multiple Myeloma Research and Treatments (23 papers), Bone health and treatments (7 papers) and Protein Degradation and Inhibitors (6 papers). Evgenia Verrou is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), Bone health and treatments (7 papers) and Protein Degradation and Inhibitors (6 papers). Evgenia Verrou collaborates with scholars based in Greece, United Kingdom and United States. Evgenia Verrou's co-authors include Eirini Katodritou, Evangelos Terpos, Kostas Zervas, Konstantinos Vahtsevanos, Konstantinos Zervas, Anastasia Banti, Meletios Α. Dimopoulos, Dimitra Mihou, Stefanos Triaridis and Kyriaki Kitikidou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Evgenia Verrou

30 papers receiving 1.1k citations

Peers

Evgenia Verrou

ONCOL

OSM

HEMAT

RHEUM

D. Christoulas Greece

Kostas Zervas Greece

F. Geurs Belgium

Konstantinos Tsionos Greece

Raffaello Bertieri Italy

Vassiliki Koutsoukou Greece

Gian-Matteo Pica Italy

S. Rogers United Kingdom

Thomas Nösslinger Austria

Eva Löfvenberg Sweden

D. Christoulas Greece

Evgenia Verrou

737 ×0.8

ONCOL

263 ×0.5

OSM

638 ×1.4

HEMAT

442 ×2.1

70 ×0.5

RHEUM

Citations per year, relative to Evgenia Verrou Evgenia Verrou (= 1×) peers D. Christoulas

Countries citing papers authored by Evgenia Verrou

Since Specialization

Citations

This map shows the geographic impact of Evgenia Verrou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evgenia Verrou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evgenia Verrou more than expected).

Fields of papers citing papers by Evgenia Verrou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evgenia Verrou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evgenia Verrou. The network helps show where Evgenia Verrou may publish in the future.

Co-authorship network of co-authors of Evgenia Verrou

This figure shows the co-authorship network connecting the top 25 collaborators of Evgenia Verrou. A scholar is included among the top collaborators of Evgenia Verrou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evgenia Verrou. Evgenia Verrou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Katodritou, Eirini, Efstathios Kastritis, Despina Fotiou, et al.. (2025). Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group. Clinical Lymphoma Myeloma & Leukemia. 25(6). e359–e365.

Terpos, Evangelos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, et al.. (2024). Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA. American Journal of Hematology. 99(3). 396–407. 10 indexed citations

Fylaktou, Asimina, et al.. (2024). HLA variations in patients with diffuse large B-cell lymphoma and association with disease risk and prognosis: a case-control study. Frontiers in Genetics. 15. 1341822–1341822. 1 indexed citations

Gavriilaki, Eleni, Foteini Theodorakakou, Christine‐Ivy Liacos, et al.. (2022). Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. Journal of Clinical Medicine. 11(12). 3355–3355. 8 indexed citations

Verrou, Evgenia, et al.. (2021). Chronic myelogenous leukemia occurring in two brothers: The opposite sides of the same coin?. SHILAP Revista de lepidopterología. 16. 100261–100261. 2 indexed citations

Terpos, Evangelos, E. Yiannaki, Dimitra Markala, et al.. (2019). Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome. Annals of Hematology. 98(6). 1457–1466. 15 indexed citations

Katodritou, Eirini, Evangelos Terpos, Janet North, et al.. (2011). Tumor‐primed natural killer cells from patients with multiple myeloma lyse autologous, NK‐resistant, bone marrow‐derived malignant plasma cells. American Journal of Hematology. 86(12). 967–973. 15 indexed citations

Kyrgidis, Αthanassios, et al.. (2010). Reply to I. Abraham. Journal of Clinical Oncology. 28(9). e145–e147.

Katodritou, Eirini, Evgenia Verrou, Persefoni Xirou, et al.. (2009). Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?. Leukemia Research. 33(8). 1137–1140. 32 indexed citations

10.

Verrou, Evgenia, et al.. (2008). Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study. Annals of Oncology. 19(10). 1765–1769. 12 indexed citations

11.

Katodritou, Eirini, et al.. (2008). Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?. Leukemia Research. 32(7). 1153–1156. 21 indexed citations

12.

Katodritou, Eirini, Evgenia Verrou, & Konstantinos Zervas. (2008). ESAs: Not a convicted felon but still a suspect. American Journal of Hematology. 83(11). 880–881. 1 indexed citations

13.

Katodritou, Eirini, et al.. (2008). Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma. American Journal of Hematology. 83(9). 697–701. 22 indexed citations

14.

Katodritou, Eirini, Charalambos Kartsios, Evgenia Verrou, et al.. (2007). Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: First reported case. Leukemia Research. 32(2). 339–341. 19 indexed citations

15.

Katodritou, Eirini, Evangelos Terpos, Konstantinos Zervas, et al.. (2007). Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Annals of Hematology. 86(5). 369–376. 18 indexed citations

16.

Dimopoulos, Meletios Α., Konstantinos Anargyrou, Eirini Katodritou, et al.. (2007). The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma.. Blood. 110(11). 1478–1478. 1 indexed citations

17.

Zervas, Kostas, Evgenia Verrou, Konstantinos Vahtsevanos, et al.. (2006). Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients. British Journal of Haematology. 134(6). 620–623. 212 indexed citations

18.

Terpos, Evangelos, et al.. (2006). Bortezomib is an effective agent for MDS/MPD syndrome with 5q− anomaly and thrombocytosis. Leukemia Research. 31(4). 559–562. 23 indexed citations

19.

Terpos, Evangelos, Deborah J. Heath, Amin Rahemtulla, et al.. (2006). Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. British Journal of Haematology. 135(5). 688–692. 170 indexed citations

20.

Terpos, Evangelos, Deborah J. Heath, Amin Rahemtulla, et al.. (2006). Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.. Blood. 108(11). 506–506. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact